Identification
NamePotassium
Accession NumberDB01345
TypeSmall Molecule
GroupsApproved
Description

Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.

Structure
Thumb
Synonyms
K
Kalium
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Potassium acetateM911911U02 127-08-2SCVFZCLFOSHCOH-UHFFFAOYSA-MDetails
Potassium sulfate1K573LC5TV 7778-80-5OTYBMLCTZGSZBG-UHFFFAOYSA-LDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
K Lyte Cl PwrPowder, for solution1.86 gOralBristol Labs Division Of Bristol Myers Squibb1965-12-311997-08-14Canada
Polycitra-KSolution398 mgOralJanssen Pharmaceuticals1996-12-312009-10-02Canada
Polycitra-KPowder1.193 gOralAlza1996-12-312001-08-01Canada
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousHospira, Inc.1984-07-20Not applicableUs
Potassium AcetateInjection, solution, concentrate196.3 mg/mLIntravenousHospira, Inc.1984-07-20Not applicableUs
Potassium AcetateLiquid392 mgIntravenousSandoz Canada Incorporated1988-12-312016-10-24Canada
Potassium Acetate Inj 2meq/mlSolution2 meqIntravenousAbbott1984-12-312008-06-06Canada
Potassium Acetate Inj 392mg/ml USPLiquid392 mgIntravenousLyphomed, Division Of Fujisawa Canada Inc.1984-12-311996-09-10Canada
Potassium Acetate InjectionSolution392 mgIntravenousFresenius Kabi1984-12-31Not applicableCanada
Potassium Acetate Injection USPLiquid39.2 %IntravenousOmega Laboratories Ltd2016-07-18Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousExela Pharma Sciences, Llc.2016-01-07Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Complexed Potassium Tablets - 99mgTablet99 mgOralAlbion1996-09-062002-07-12Canada
K Lyte Tab Lime & Orange FlavTablet, effervescent975 mgOralBristol Labs Division Of Bristol Myers Squibb1965-12-311997-08-14Canada
Port A Mins Super Potassium 99Tablet99 mgOralGreat Earth Companies, Inc.1998-08-252002-10-02Canada
Potassium 250Capsule250 mgOralSeroyal International Inc.1997-12-122009-07-06Canada
Potassium 99 - CapletTablet99 mgOralHealth Wise Nutrition Inc.1995-12-312002-07-18Canada
Potassium 99mg TabletsTablet99 mgOralBioforce Canada Inc.1994-12-311997-04-14Canada
Potassium Gluconate Tab 550mg USPTablet92 mgOralPharmavite1991-12-312000-08-24Canada
Potassium Gluconate Tablets 99mg USPTablet99 mgOralRoyal Bodycare Canada Inc.1992-12-312001-08-07Canada
Potassium RougierLiquid780 mgOralRougier Pharma Division Of Ratiopharm Inc1965-12-312001-09-05Canada
Potassium Tab 99mgTablet99 mgOralDa Vinci Laboratories, Division Of Foodscience Corporation1981-12-311997-05-08Canada
Potassium Tab 99mgTablet99 mgOralRheingold Food International Ltd.1985-12-312007-07-26Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium AcetateInjection, solution196 mg/mLIntravenousAmerican Regent1990-09-30Not applicableUs
Potassium AcetateInjection, solution, concentrate392 mg/mLIntravenousAmerican Regent1990-09-302017-07-21Us
International BrandsNot Available
Brand mixtures
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AlphaligoTabletOralClinique Lafontaine Inc, Division Les Importations Ortho1998-03-062008-08-07Canada
AminosynInjection, solutionIntravenousHospira, Inc.2011-03-23Not applicableUs
Aminosyn 3.5% MLiquidIntravenousAbbott1980-12-311999-08-09Canada
Aqua-S SupplementTabletOralGarden State NutritionalsNot applicableNot applicableCanada
B 6 PlusTabletOralAnabolic Laboratories Inc.1967-12-312004-03-15Canada
BseltzerGranule, effervescentOralAbundance Marketing Ltd.2001-11-112007-07-23Canada
Buffered Vitamin C Powder With Ca Mg and KPowderOralThorne Research Inc.1997-04-182005-06-21Canada
Buffered Vitamin C Pwr W Cal-mag-potassiumPowderOralSisu Inc.1987-12-312009-08-04Canada
C-1000 Plus Zinc & PotassiumTabletOralNu Life Nutrition Ltd.1987-12-312005-03-15Canada
C.R.D.-forceCapsuleOralPrairie Naturals2001-09-192006-09-20Canada
Cal & Mag Hvp Chel Plus C Potass & Zinc TabTabletOralGahler Enterprises Ltd.1989-12-312000-09-05Canada
Cal-mag (one To One) With Potass & ZincTabletOralGahler Enterprises Ltd.1988-12-311999-01-27Canada
Cal-mag Plus K, Mn and Zn CapletsTabletOralHealth Wise Nutrition Inc.1994-12-311999-08-13Canada
Calcium & Magnesium Citrate Plus D With Manganese, Potassium & ZincTabletOralNatural Factors Nutritional Products Ltd.1998-12-142008-07-17Canada
Calcium & Magnesium Plus Potassium & ZincTabletOralNatural Factors Nutritional Products Ltd.1998-12-212009-09-28Canada
Calcium & Magnesium Plus Potassium, Zinc, & ManganeseCapsuleOralNatural Factors Nutritional Products Ltd.2000-04-272008-07-17Canada
Calcium & Magnesium With Potassium & ZincTabletOralWn Pharmaceuticals Ltd.2000-08-302005-08-15Canada
Calcium & Magnesium With Potassium, Zinc, Manganese & Vitamin DTabletOralWn Pharmaceuticals Ltd.2000-08-302005-08-15Canada
Calcium and Mag-potass and Zinc CapCapsuleOralGahler Enterprises Ltd.1991-12-312001-07-26Canada
Calcium and Magnesium 1:1 Plus TabletsTabletOralAlbi Naturals1998-02-202009-07-15Canada
Calcium Magnesium With Potassium TabTabletOralNutrition For Life International1996-11-271998-09-01Canada
Calcium-magnesium With K & Zn and Vitamin D3CapsuleOralHolista Health (Canada) Inc.1997-08-152002-08-06Canada
Chela Potassium PlusTabletOralNu Life Nutrition Ltd.1988-12-312000-03-03Canada
Cmp PlexTabletOralNutraceutical Corporation2003-09-022006-08-02Canada
Coenzyme Q10 Isotonix Vitamin and Mineral SupplementPowderOralMarket America2002-06-042008-09-04Canada
ColPrep KitPowder, for solutionOralKvk Tech,Inc2016-12-27Not applicableUs
Complete Multivitamins and Minerals Tablets Timed ReleaseTablet, extended releaseOralPharmetics (2011) Inc.1999-07-262009-07-30Canada
Dual MixPowderOralOmnilife Manufactura, S.A. De C.V.2003-11-032008-08-20Canada
EnviveCapsuleOralSisu Inc.2002-04-012006-07-31Canada
Extra P.N. Vitamin-mineral Drink MixPowderOralChanges InternationalNot applicableNot applicableCanada
Flex CapsulesCapsuleOralFoodscience Laboratories, Division Of Foodscience Corporation1998-07-022006-06-16Canada
Formula BPTabletOralNutrivention Nutritional ProductsNot applicableNot applicableCanada
Formula InfCapsuleOralBalance Plus, Inc.2000-02-092004-08-17Canada
Formula JsTabletOralNutrivention Nutritional ProductsNot applicableNot applicableCanada
Formula R TabTabletOralMetagenics, Inc.1997-03-052006-08-29Canada
Formula WbTabletOralNutrivention Nutritional ProductsNot applicableNot applicableCanada
Formule No 204 Profil TabTabletOralPharmalab Inc.1987-12-312001-07-30Canada
Hi Potency B Complex W Chelated MineralsTabletOralKlaire Labs Inc.1984-12-312004-01-19Canada
Hyperlyte (multi-electrolyte Concentrate)LiquidIntravenousB. Braun Medical Inc.1998-09-04Not applicableCanada
Hyperlyte CRInjection, solution, concentrateIntravenousB. Braun Medical Inc.2012-04-12Not applicableUs
Hyperlyte CR Multi-electrolyte ConcentrateLiquidIntravenousB. Braun Medical Inc.1998-09-03Not applicableCanada
Hypo Vites TabTabletOralPharmetics (2011) Inc.1977-12-312006-07-27Canada
Iode-potassiumTabletOralGamme Nature1999-12-302004-07-26Canada
Iodine-potassium TabletsTabletOralLe Naturiste J.M.B. Inc.1986-12-312000-01-12Canada
Isotonix Advanced B-complex Vitamins With Potassium and MagnesiumPowderOralMarket America2004-01-272009-07-20Canada
Isotonix Calcium Plus FormulaPowderOralMarket America1998-12-172001-06-28Canada
Isotonix Vitamin B-folic Acid-mineral SupplePowderOralMarket America1996-12-312004-07-12Canada
Kanga Sport Vitamins B & C Plus MineralsTablet, effervescentOralLacombe Drugs (1992) LtdNot applicableNot applicableCanada
Kenwood Liquid SupplementLiquidOralKenwood Laboratories (Division Of Bradley Pharmaceuticals)Not applicableNot applicableCanada
Kmg PlusCapsuleOralSeroyal International Inc.1994-12-312009-07-06Canada
L.G.I.T.CapsuleOralMorinda Canada1999-12-152001-07-23Canada
LypholyteSolutionIntravenousPartners Health Care, Inc.1996-08-142008-01-10Canada
Lypholyte Multi-electrolyte Conc InjLiquidIntravenousLyphomed, Division Of Fujisawa Canada Inc.1991-12-311996-09-10Canada
LyteprepPowder, for solutionOralTherapex Division De E Z Em Canada Inc1987-12-312000-04-26Canada
MagnacalCapsuleOralHolista Health (Canada) Inc.2002-09-112008-07-17Canada
MgkCapsuleOralHorizon SantÉ International Inc.Not applicableNot applicableCanada
MineralexLiquidOralLand Art Inc.2001-11-122008-06-26Canada
Multi Vitamins & MineralsTabletOralWn Pharmaceuticals Ltd.2000-01-122001-04-12Canada
Multi-min Electro C Pow Plus B2Granule, effervescentOralQuest Vitamins A Div Of Purity Life Health Products1988-12-311998-07-15Canada
Multi-vitamins With MineralsTabletOralWn Pharmaceuticals Ltd.2001-04-122009-09-28Canada
Multimineral ChelatesTabletOralW.R. Enterprises Inc.1984-12-312002-08-01Canada
N.U.T. ComplexTabletOralAbundance Marketing Ltd.2000-12-062004-06-30Canada
Neutral C + Coenzyme Q10 Plus Vitamins & MineralsCapsuleOralNew Vision Nutritionals Company1998-06-072002-11-20Canada
Normosol M With Dextrose 5%SolutionIntravenousHospira, Inc.1965-12-31Not applicableCanada
Nutrilite Double XTabletOralNutrilite, A Division Of Access Business Group, Llc2002-12-152008-06-24Canada
NutrilyteInjection, solution, concentrateIntravenousAmerican Regent1990-09-30Not applicableUs
Nutrilyte IIInjection, solution, concentrateIntravenousAmerican Regent1990-10-012017-07-26Us
OnccorTabletOralSimone Protective Pharmaceuticals, Inc.Not applicableNot applicableCanada
One A Day Advance AdultsTabletOralBayer Inc Consumer Care2002-09-122007-08-02Canada
One A Day Advance Adults 50+TabletOralBayer Inc Consumer Care2002-09-122007-08-02Canada
One A Day TabTabletOralCountry Health Laboratories Ltd.1982-12-312001-07-27Canada
Orange Flavored Crystal Chews TabTabletOralJeunique International Inc.1998-02-172006-07-20Canada
Osteo FormulaTabletOralGeneral Nutrition Canada Inc.2001-10-152005-08-05Canada
Plasma-lyte 56 5% Dextrose InjLiquidIntravenousBaxter Laboratories1990-12-312014-04-17Canada
Potassium and Iodine TabTabletOralAlbi Naturals1979-12-312008-07-17Canada
PurigoLiquidTopicalSun Jin Yu Ji Co2017-08-01Not applicableUs
Q-10 PlusCapsuleOralThorne Research Inc.1997-09-092005-08-26Canada
Spectra 301 Vitamin and Mineral SuppTabletOralNf Formulas Inc.1986-12-312000-07-05Canada
Spectrum 2 CapCapsuleOralNf Formulas Inc.1988-12-312008-06-26Canada
Super C-M-KTabletOralCreative Nutrition Canada Corp.1986-12-312007-07-11Canada
Super Charged EnergyPowderOralSimone Protective Pharmaceuticals, Inc.Not applicableNot applicableCanada
Super Daily No 2TabletOralW.R. Enterprises Inc.1990-12-312003-07-30Canada
Super-cellCapsuleOralBody Wise International LlcNot applicableNot applicableCanada
SUPREP Bowel PrepSolution, concentrateOralBraintree Laboratories2010-08-06Not applicableUs
Tar-endCapsuleOralNatures Sunshine Products, Inc.1999-05-252006-07-10Canada
Tri-mins - CapCapsuleOralAlbion1996-09-062007-10-19Canada
Twin Ultra Liquid Fruit Punch FlavorLiquidOralTwin Laboratories Inc.1995-12-312002-09-11Canada
Twin Ultra Liquid Grape FlavorLiquidOralTwin Laboratories Inc.1995-12-312007-08-01Canada
Twin Ultra Liquid Lemon-lime FlavorLiquidOralTwin Laboratories Inc.1995-12-312005-08-30Canada
Twin Ultra Liquid Orange FlavorLiquidOralTwin Laboratories Inc.1995-12-312002-09-11Canada
Vimeral TabTabletOralIcn Pharmaceuticals1979-12-312005-04-26Canada
Vit C W Calc-mag and Potass PowderPowder, for solutionOralNf Formulas Inc.1986-12-312000-07-05Canada
Vitalife - CapsuleCapsuleOralHolista Health (Canada) Inc.1996-11-132002-08-06Canada
Women's FormulaTabletOralPro Ma Systems1998-10-312007-09-25Canada
Z-force Vitamin and Mineral SupplementCapsuleOralDymatize Enterprises Inc.2001-12-122006-10-06Canada
Z-mass PM Vitamin and Mineral SupplementCapsuleOralCytodyne Technologies Inc.2001-02-282004-10-22Canada
Categories
UNIIRWP5GA015D
CAS number7440-09-7
WeightAverage: 39.0983
Monoisotopic: 38.96370649
Chemical FormulaK
InChI KeyZLMJMSJWJFRBEC-UHFFFAOYSA-N
InChI
InChI=1S/K
IUPAC Name
potassium
SMILES
[K]
Pharmacology
Indication

Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.

TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium/potassium-transporting ATPase subunit alpha-1ProteinunknownNot AvailableHumanP05023 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of elimination

Mostly urine but also skin and feces.

Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Pyruvate MetabolismMetabolicSMP00060
Indapamide Action PathwayDrug actionSMP00110
Trichlormethiazide Action PathwayDrug actionSMP00121
Amiloride Action PathwayDrug actionSMP00133
Rabeprazole Action PathwayDrug actionSMP00229
Alprenolol Action PathwayDrug actionSMP00297
Quinidine Action PathwayDrug actionSMP00323
Lidocaine (Antiarrhythmic) Action PathwayDrug actionSMP00328
Tocainide Action PathwayDrug actionSMP00330
Ibutilide Action PathwayDrug actionSMP00332
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00340
Diltiazem Action PathwayDrug actionSMP00359
Lesch-Nyhan Syndrome (LNS)DiseaseSMP00364
Labetalol Action PathwayDrug actionSMP00368
Verapamil Action PathwayDrug actionSMP00375
Amlodipine Action PathwayDrug actionSMP00376
Nimodipine Action PathwayDrug actionSMP00380
Levobupivacaine Action PathwayDrug actionSMP00397
Oxymorphone Action PathwayDrug actionSMP00412
Fentanyl Action PathwayDrug actionSMP00415
Fluoxetine Action PathwayDrug actionSMP00426
Nicotine Action PathwayDrug actionSMP00431
Spermidine and Spermine BiosynthesisMetabolicSMP00445
Lactose DegradationMetabolicSMP00457
Myoadenylate deaminase deficiencyDiseaseSMP00537
Pyruvate kinase deficiencyDiseaseSMP00559
Levorphanol Action PathwayDrug actionSMP00673
Anileridine Action PathwayDrug actionSMP00674
Methadyl Acetate Action PathwayDrug actionSMP00678
Buprenorphine Action PathwayDrug actionSMP00684
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Potassium.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Potassium.Experimental, Illicit
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Potassium.Experimental, Illicit, Withdrawn
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Potassium.Illicit, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Potassium.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Potassium.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Potassium.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium.Approved, Illicit
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Potassium.Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Potassium.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium.Approved, Illicit, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Potassium.Approved, Illicit
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium.Approved, Illicit
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Potassium.Illicit
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Potassium.Approved, Illicit
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Potassium.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Potassium.Approved, Illicit
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium.Approved, Investigational, Vet Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Potassium.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Potassium.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

John B. Sardisco, "Production of potassium sulfate and hydrogen chloride." U.S. Patent US4045543, issued 1865.

US4045543
General ReferencesNot Available
External Links
ATC CodesC03AB02 — Hydroflumethiazide and potassiumC03AB04 — Chlorothiazide and potassiumC03BB07 — Clofenamide and potassiumC03CB02 — Bumetanide and potassiumC03AB03 — Hydrochlorothiazide and potassiumC03AB07 — Cyclopenthiazide and potassiumC03AB06 — Trichlormethiazide and potassiumC03AB01 — Bendroflumethiazide and potassiumC03BB03 — Clopamide and potassiumC03AB05 — Polythiazide and potassiumC03BB04 — Chlortalidone and potassiumC03CB01 — Furosemide and potassiumB05XA17 — Potassium acetateC03AB09 — Cyclothiazide and potassiumC03AB08 — Methyclothiazide and potassiumC03BB05 — Mefruside and potassiumC03BB02 — Quinethazone and potassium
AHFS Codes
  • 40:12.00
  • 40:28.92
  • 40:34.00*
  • 68:36.08
  • 84:92.00
  • 88:29.00*
  • 92:00.00
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (632 KB)
MSDSDownload (72.2 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHypertensive1
1RecruitingTreatmentStroke, Ischemic1
1, 2CompletedSupportive CareHypertensive / Pre-Hypertension1
2CompletedPreventionBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases1
2CompletedTreatmentBorderline Hypokalemia1
2CompletedTreatmentHyperglycemias / Strokes1
3CompletedTreatmentLeukemias1
3Not Yet RecruitingTreatmentCardiac Arrythmias1
4Unknown StatusTreatmentAcute Hypokalemia1
Not AvailableCompletedBasic ScienceBlood Pressures / Hypertensive / Renal Function / Vascular Function1
Not AvailableCompletedScreeningOther Diseases or Conditions1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus / Vascular Diseases1
Not AvailableRecruitingTreatmentCorneal Opacity1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous
CapsuleOral
TabletOral
Tablet, extended releaseOral
Injection, solution, concentrateIntravenous
PowderOral
Powder, for solutionOral1.86 g
Tablet, effervescentOral975 mg
Tablet, effervescentOral
SolutionIntravenous
LiquidIntravenous
Granule, effervescentOral
PowderOral1.193 g
SolutionOral398 mg
CapsuleOral250 mg
Injection, solutionIntravenous196 mg/mL
Injection, solution, concentrateIntravenous196.3 mg/mL
Injection, solution, concentrateIntravenous3.93 g/20mL
Injection, solution, concentrateIntravenous392 mg/mL
SolutionIntravenous2 meq
LiquidIntravenous392 mg
SolutionIntravenous392 mg
LiquidIntravenous39.2 %
TabletOral92 mg
TabletOral99 mg
LiquidOral780 mg
LiquidTopical
Solution, concentrateOral
LiquidOral
Powder, for solutionOral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6946149 No2003-03-072023-03-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)63.38 °CNot Available
boiling point (°C)770°CNot Available
water solubilitySolubleNot Available
Predicted Properties
PropertyValueSource
logP0.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as homogeneous alkali metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkali metal atom.
KingdomChemical entities
Super ClassInorganic compounds
ClassHomogeneous metal compounds
Sub ClassHomogeneous alkali metal compounds
Direct ParentHomogeneous alkali metal compounds
Alternative ParentsNot Available
SubstituentsHomogeneous alkali metal
Molecular FrameworkNot Available
External Descriptorsalkali metal atom (CHEBI:26216 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Uniprot Name:
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight:
112895.01 Da
References
  1. Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [PubMed:17334838 ]
  2. Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [PubMed:17347782 ]
  3. Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [PubMed:17366541 ]
  4. Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [PubMed:17369284 ]
  5. Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [PubMed:17444965 ]
Drug created on June 30, 2007 12:13 / Updated on September 01, 2017 10:38